J.L. Bainbridge & Co’s Atossa Therapeutics ATOS Stock Holding History

J.L. Bainbridge & Co’s Portfolio ATOS Stock Details ATOS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-741	Closed	-$6.56K	–	108
2025 Q4	$6.56K	Hold	741	–	–	﹤0.01%	107
2025 Q3	$9.64K	Hold	741	–	–	﹤0.01%	107
2025 Q2	$9.23K	Hold	741	–	–	﹤0.01%	105
2025 Q1	$7.48K	Hold	741	–	–	﹤0.01%	101
2024 Q4	$10.5K	Hold	741	–	–	﹤0.01%	105
2024 Q3	$16.9K	Hold	741	–	–	﹤0.01%	104
2024 Q2	$13.2K	Hold	741	–	–	﹤0.01%	92
2024 Q1	$20K	Hold	741	–	–	﹤0.01%	89
2023 Q4	$9.79K	Hold	741	–	–	﹤0.01%	83
2023 Q3	$8.19K	Buy	741 +33	+5%	+$479	﹤0.01%	77
2023 Q2	$13.4K	Hold	708	–	–	﹤0.01%	76
2023 Q1	$7.7K	Hold	708	–	–	﹤0.01%	73
2022 Q4	$5.61K	Hold	708	–	–	﹤0.01%	74
2022 Q3	$9K	Hold	708	–	–	﹤0.01%	71
2022 Q2	$12K	Hold	708	–	–	﹤0.01%	76
2022 Q1	$13K	Hold	708	–	–	﹤0.01%	89
2021 Q4	$17K	Hold	708	–	–	﹤0.01%	90
2021 Q3	$35K	Hold	708	–	–	﹤0.01%	94
2021 Q2	$67K	Buy	+708	New	+$37.5K	0.01%	91

Other funds holding ATOS

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

VFT

Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

J.L. Bainbridge & Co's ATOS Position: Q1 2026 in Review

J.L. Bainbridge & Co sold out of Atossa Therapeutics (ATOS) in Q1 2026, closing a stake of 741 shares — an estimated $6.56K sold.

J.L. Bainbridge & Co first reported a position in ATOS in Q2 2021 and held it in 19 quarters. The position peaked at $67K in Q2 2021. 33 funds tracked by Wall St. Rank hold ATOS as of Q1 2026.

J.L. Bainbridge & Co reported no remaining Atossa Therapeutics position as of Q1 2026 after selling out during the quarter.
J.L. Bainbridge & Co sold 741 Atossa Therapeutics shares in Q1 2026, an estimated $6.56K.
J.L. Bainbridge & Co first reported a position in Atossa Therapeutics in Q2 2021 and held it in 19 quarters.
J.L. Bainbridge & Co's Atossa Therapeutics position peaked at $67K in Q2 2021.
33 funds tracked by Wall St. Rank held Atossa Therapeutics as of Q1 2026.

Based on J.L. Bainbridge & Co's 13F filing for Q1 2026, filed 22 Apr 2026.